KRAS-Targeting Pill Extends Survival in Metastatic Pancreatic Cancer
TL;DR Summary
A KRAS-targeting pill called daraxonrasib nearly doubles median survival in metastatic pancreatic cancer, boosting it from 6.7 to 13.2 months in a 500-patient randomized trial after prior treatment, with fewer severe side effects; experts say it could become the new standard of care and researchers will study earlier use and KRAS subtypes. FDA expedited review and expanded-access programs are planned, and results were published in NEJM and presented at ASCO.
- Breakthrough Pill Nearly Doubles Survival Time For One of The Deadliest Cancers ScienceAlert
- After new drug’s ‘unprecedented’ results for pancreatic cancer, doctors look at other uses NBC News
- Daily pill doubles survival time for pancreatic cancer patients BBC
- ‘Landmark’ pancreatic cancer drug keeps patients alive for twice as long The Washington Post
- ASCO: RevMed confident in Ras leadership as rivals square up Fierce Biotech
Reading Insights
Total Reads
0
Unique Readers
9
Time Saved
6 min
vs 7 min read
Condensed
94%
1,205 → 70 words
Want the full story? Read the original article
Read on ScienceAlert